Skip to main content

DESARROLLO Y EVALUACION PRECLINICA DE NUEVOS AGENTES FARMACOLOGICOS CON VECTORIZACION ENTEROHEPATICA

PID2022-140210OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE SALAMANCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bile acids in liver and gastrointestinal cancer

  • Monte, Maria J.
  • Fàbrega, Laura
  • Romero, Marta R.
  • Temprano, Alvaro G.
  • Kaplowitz, Neil
  • García-Ruiz, Carmen
  • Marin, Jose J. G.
  • Fernández-Checa, José C.
Bile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol catabolism, they are now acknowledged to play intricate roles in regulating intermediary metabolism by controlling the expression of crucial genes. Additionally, they exert a significant impact on inflammation, cytotoxicity, and carcinogenesis. Moreover, BAs have a critical impact on the crosstalk between gut microbiota and host physiology, which affects the progression of liver and gastrointestinal cancers. Clinical data and results from studies of animal models support the involvement of BAs in the development of hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and pancreatic cancer. On the other hand, BAs and their derivatives have been proposed as pharmacological tools in strategies to restore abnormal hepatobiliary function and target cytostatic agents to cancers of the enterohepatic circuit. In the present review, we summarize basic concepts of BA physiology and regulation, as well as new advances in this expanding field of renewed interest for cancer biology, lending further support for the key role of BAs in liver and gastrointestinal cancer., We acknowledge the support from grants PID2019-111669RB-100, PID2020-115055RB-I00, PID2022-142956OB-100, PID2022-140210OB-100, PID2023-1488030B-100, 2024AEP053; 2023AEPP068 and 2020AEPP145 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI); Plan Nacional sobre Drogas grant 2024; and PI22/00526 from the Fondo de Investigaciones Sanitarias, Instituto Salud Carlos III, Spain co-funded by European Regional Development Fund/European Social Fund, Junta Castilla y Leon (SA113/P23) and from the CIBEREHD; as well as support from AGAUR of the Generalitat de Catalunya SGR-2021–00491, and funding from the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, as well as support from National Cancer Institute PO1 CA281819–01A1 from the NIH. L.F. is supported by a Jaume Bosch contract from the CIBEREHD, and she is a PhD student of the Biomedicine Program of the University of Barcelona, Spain., Peer reviewed